Xaira Therapeutics
PrivateLast Round
Series A
Apr 23, 2024
Est. Valuation
$2.7B
Total Funding Raised
$1B
Momentum
Top 5%
of companies Caplight tracks
Company Overview
Xaira Therapeutics is a biotechnology company that leverages artificial intelligence to enhance drug discovery and development through comprehensive product development and data generation.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Medical AI, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Foundation
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Xaira Therapeutics Comparables
Compare Xaira Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Insitro | 87% | |
| Valo Health | 83% | |
| Generate Biomedicines | 83% |
Xaira Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Apr 23, 2024 |
Key People
Founding team and executive leadership
Xaira Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Breyer Capital | Series A |
| SV Angel | Series A |
| New Enterprise Associates (NEA) | Series A |
| ARCH Venture Partners | Series A |
| F-Prime Capital | Series A |
| WRF Capital | Series A |
| Risk and Return | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 21, 2026
Monthly visitors grew 123% MoM, reaching 47.1K.
- Jun 21, 2026
Developing a next-generation Vision AI platform for autonomous labs.
Recent news
Latest coverage and updates
- hiresJul 6, 2026
Xaira Therapeutics, Inc. hired Ian McCaffery as Senior Vice President of Translational Science and Early Clinical Development on Jul 6th '26.
- is_developingJul 6, 2026
Xaira Therapeutics, Inc. is developing pipeline of AI-designed medicines on Jul 6th '26.
- promotesJul 6, 2026
Xaira Therapeutics, Inc. promoted Bo Wang to Chief AI Scientist on Jul 6th '26.
- promotesJul 6, 2026
Xaira Therapeutics, Inc. promoted Ci Chu to Chief Discovery Officer on Jul 6th '26.
Xaira Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Xaira Therapeutics's valuation, stock price, and market status.
Is Xaira a public or private company?
Xaira is a private company.
What is the current stock price of Xaira?
Xaira is a private company with no public stock price. No recent secondary market data is available.
How much is Xaira worth (valuation)?
Xaira's valuation is estimated at $2.7B based on funding round data.
Can I buy Xaira stock?
Xaira shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Xaira's last funding round?
Xaira's most recent funding round was Series A on April 23, 2024.
Who are the main investors in Xaira?
Key investors in Xaira include ARCH Venture Partners, ARCH Venture Partners, Foresite Capital, Foresite Labs.
Will Xaira IPO soon?
No public IPO plans have been announced for Xaira.
How can I track Xaira secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Xaira's secondary market activity and sign up for updates.